Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

110.50
-0.0338-0.03%
Post-market: 110.500.00000.00%19:30 EDT
Volume:108.64K
Turnover:12.04M
Market Cap:1.00B
PE:89.54
High:111.36
Open:110.76
Low:110.19
Close:110.53
52wk High:118.00
52wk Low:85.91
Shares:9.09M
Float Shares:9.09M
Volume Ratio:0.54
T/O Rate:1.20%
Dividend:2.18
Dividend Rate:1.97%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):142.31

Loading ...

Morgan Stanley downgrades Novo Nordisk (0QIU) to a Sell

TIPRANKS
·
Sep 11

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
Sep 11

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage

TIPRANKS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

Novartis shareholder calls for board changes, Reuters reports

TIPRANKS
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures

MT Newswires Live
·
Sep 10

Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment

MT Newswires Live
·
Sep 10